Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
33 hedge funds and large institutions have $1.83M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
6% less funds holding
Funds holding: 35 → 33 (-2)
8% less capital invested
Capital invested by funds: $1.99M → $1.83M (-$165K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$166K |
| 2 |
CAC
Cowen and Company
New York
|
+$49.8K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$13.4K |
| 4 |
LC
Lindbrook Capital
Calabasas,
California
|
+$7.47K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$10.6M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$99.7K |
| 3 |
ICM
Ionic Capital Management
New York
|
-$85.8K |
| 4 |
TCA
Taconic Capital Advisors
New York
|
-$23.1K |
| 5 |
SG
StoneX Group
New York
|
-$10.8K |
DNA.WS Hedge Fund Activity: Q3 2023 in Review
33 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q3 2023, worth a combined $1.83M — down 8.3% from $1.99M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DNA.WS and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was LMR Partners, adding an estimated $166K. The largest seller was Guggenheim Capital, cutting an estimated $10.6M.
- 33 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q3 2023, down from 35 in Q2 2023.
- Funds reported $1.83M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q3 2023, down 8.3% quarter-over-quarter.
- 3 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q3 2023 and 5 closed out, a net change of -2 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q3 2023 was LMR Partners, an estimated $166K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q3 2023 was Guggenheim Capital, an estimated $10.6M sold.
Based on aggregated 13F filings for Q3 2023.